Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334885094> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2334885094 endingPage "328" @default.
- W2334885094 startingPage "1" @default.
- W2334885094 abstract "Introduction: Dexmedetomidine is an alpha-2 receptor agonist indicated for intensive care unit and procedural sedation. In addition to its sedative properties, dexmedetomidine has sympatholytic effects that reduce heart rate and blood pressure. Alcohol withdrawal is characterized by agitation, psychosis, and manifestations of autonomic hyperactivity. The objective of this study was to evaluate the use of adjunctive dexmedetomidine for severe alcohol withdrawal. Hypothesis: Addition of dexmedetomidine results in reduced benzodiazepine use, withdrawal symptoms, and causes minimal side effects. Methods: This retrospective study evaluated patients >18 years old with severe alcohol withdrawal treated with dexmedetomidine in conjunction with the standard of care. Patients without a Clinical Institute Withdrawal Assessment (CIWA) score of?8 or those prescribed dexmedetomidine for other indications were excluded. Patient vital signs, CIWA scores, benzodiazepine use, and dexmedetomidine doses and duration were compared pre- and post-dexmedetomidine initiation. Paired t-tests were utilized to compare continuous variables, with p<0.05 considered significant. Results: Sixteen patients were enrolled. The majority of patients were male (94%) with an average age of 44.3 ± 13.6 years. The mean APACHE II score was 16.1 ± 8.2, and mean length of stay in the ICU was 131.8 ± 65.9 hours. Average duration of dexmedetomidine was 40.4 ± 39.2 hours at a mean dose of 0.52 ± 0.23 mcg/kg/hour started 41.7 ± 20.2 hours after admission. Total benzodiazepine exposure, represented by milligrams of lorazepam equivalents, was less after initiating dexmedetomidine (39.4 ± 28 vs 18.2 ± 18; p=0.018), as was the average CIWA score (14.5 ± 4.2 vs 9.0 ± 4.6; p=0.004). Heart rate (106.8 ± 15.9 vs 82.7 ± 12.4; p=0.0001) and systolic blood pressure (135.8 ± 15.2 vs 124.6 ± 20.6; p=0.035) were reduced with the addition of dexmedetomidine. Bradycardia (HR?60) or hypotension (SBP?90) each occurred in 25% of patients and both occurred in 6% of patients. Conclusions: The addition of dexmedetomidine blunts the symptoms of autonomic hyperactivity and reduces benzodiazepine requirements; however, these beneficial effects must be weighed against the risk of bradycardia and hypotension." @default.
- W2334885094 created "2016-06-24" @default.
- W2334885094 creator A5040757935 @default.
- W2334885094 creator A5058882437 @default.
- W2334885094 creator A5065520294 @default.
- W2334885094 creator A5075966979 @default.
- W2334885094 creator A5077824195 @default.
- W2334885094 creator A5082697782 @default.
- W2334885094 date "2012-12-01" @default.
- W2334885094 modified "2023-09-27" @default.
- W2334885094 title "121" @default.
- W2334885094 doi "https://doi.org/10.1097/01.ccm.0000424341.32883.e7" @default.
- W2334885094 hasPublicationYear "2012" @default.
- W2334885094 type Work @default.
- W2334885094 sameAs 2334885094 @default.
- W2334885094 citedByCount "0" @default.
- W2334885094 crossrefType "journal-article" @default.
- W2334885094 hasAuthorship W2334885094A5040757935 @default.
- W2334885094 hasAuthorship W2334885094A5058882437 @default.
- W2334885094 hasAuthorship W2334885094A5065520294 @default.
- W2334885094 hasAuthorship W2334885094A5075966979 @default.
- W2334885094 hasAuthorship W2334885094A5077824195 @default.
- W2334885094 hasAuthorship W2334885094A5082697782 @default.
- W2334885094 hasConcept C126322002 @default.
- W2334885094 hasConcept C170493617 @default.
- W2334885094 hasConcept C2776376669 @default.
- W2334885094 hasConcept C2776814716 @default.
- W2334885094 hasConcept C2777602617 @default.
- W2334885094 hasConcept C2777953023 @default.
- W2334885094 hasConcept C2778173252 @default.
- W2334885094 hasConcept C2778938600 @default.
- W2334885094 hasConcept C2779706987 @default.
- W2334885094 hasConcept C2781302539 @default.
- W2334885094 hasConcept C35294091 @default.
- W2334885094 hasConcept C42219234 @default.
- W2334885094 hasConcept C71924100 @default.
- W2334885094 hasConcept C84393581 @default.
- W2334885094 hasConceptScore W2334885094C126322002 @default.
- W2334885094 hasConceptScore W2334885094C170493617 @default.
- W2334885094 hasConceptScore W2334885094C2776376669 @default.
- W2334885094 hasConceptScore W2334885094C2776814716 @default.
- W2334885094 hasConceptScore W2334885094C2777602617 @default.
- W2334885094 hasConceptScore W2334885094C2777953023 @default.
- W2334885094 hasConceptScore W2334885094C2778173252 @default.
- W2334885094 hasConceptScore W2334885094C2778938600 @default.
- W2334885094 hasConceptScore W2334885094C2779706987 @default.
- W2334885094 hasConceptScore W2334885094C2781302539 @default.
- W2334885094 hasConceptScore W2334885094C35294091 @default.
- W2334885094 hasConceptScore W2334885094C42219234 @default.
- W2334885094 hasConceptScore W2334885094C71924100 @default.
- W2334885094 hasConceptScore W2334885094C84393581 @default.
- W2334885094 hasLocation W23348850941 @default.
- W2334885094 hasOpenAccess W2334885094 @default.
- W2334885094 hasPrimaryLocation W23348850941 @default.
- W2334885094 hasRelatedWork W1540899930 @default.
- W2334885094 hasRelatedWork W2068469916 @default.
- W2334885094 hasRelatedWork W2082311304 @default.
- W2334885094 hasRelatedWork W2102017181 @default.
- W2334885094 hasRelatedWork W2141855023 @default.
- W2334885094 hasRelatedWork W2270077230 @default.
- W2334885094 hasRelatedWork W2373185700 @default.
- W2334885094 hasRelatedWork W2393876425 @default.
- W2334885094 hasRelatedWork W2588523905 @default.
- W2334885094 hasRelatedWork W2604185023 @default.
- W2334885094 hasVolume "40" @default.
- W2334885094 isParatext "false" @default.
- W2334885094 isRetracted "false" @default.
- W2334885094 magId "2334885094" @default.
- W2334885094 workType "article" @default.